Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · IEX Real-Time Price · USD
12.47
+0.47 (3.92%)
May 31, 2024, 4:00 PM EDT - Market closed
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $72.88M in the twelve months ending March 31, 2024, down -10.22% year-over-year. Revenue in the quarter ending March 31, 2024 was $17.05M, a -4.16% decrease year-over-year. In the fiscal year ending September 30, 2023, Enanta Pharmaceuticals had annual revenue of $79.20M, a decrease of -8.07%.
Revenue (ttm)
$72.88M
Revenue Growth
-10.22%
P/S Ratio
3.62
Revenue / Employee
$502,628
Employees
145
Market Cap
264.11M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | 205.20M | -1.43M | -0.69% |
| Sep 30, 2018 | 206.63M | 103.81M | 100.97% |
| Sep 30, 2017 | 102.81M | 14.55M | 16.48% |
| Sep 30, 2016 | 88.27M | -72.61M | -45.13% |
| Sep 30, 2015 | 160.88M | 113.14M | 236.98% |
| Sep 30, 2014 | 47.74M | 15.69M | 48.94% |
| Sep 30, 2013 | 32.05M | -9.65M | -23.15% |
| Sep 30, 2012 | 41.71M | -176.00K | -0.42% |
| Sep 30, 2011 | 41.88M | 19.12M | 83.99% |
| Sep 30, 2010 | 22.76M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Auna S.A. | 1.08B |
| 23andMe Holding Co. | 219.64M |
| Pulmonx | 72.99M |
| Aquestive Therapeutics | 51.50M |
| Inovio Pharmaceuticals | 717.07K |
| Atai Life Sciences | 277.00K |
ENTA News
- 4 days ago - Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference - Business Wire
- 26 days ago - Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference - Business Wire
- 27 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference - Business Wire